AbbVie to pay Genmab $750M upfront to form bispecific R&D pact

AbbVie is set to pay Genmab $750 million upfront for a stake in a pipeline of anti-cancer bispecifics led by epcoritamab. The deal, which features up to $3.2 billion in milestones, positions AbbVie to race Regeneron to market with a bispecific antibody that could compete with CAR-T therapies.